These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7781204)

  • 1. Determinants of furosemide delivery to its site of action.
    Sjöström PA; Kron BG; Odlind BG
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S38-41. PubMed ID: 7781204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saturable first-pass kinetics, plasma protein binding, and the furosemide intricacies.
    Keller F
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S24-6. PubMed ID: 7781201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evidence that urine composition affects the fraction of active furosemide in the nephrotic syndrome.
    Voelker JR; Jameson DM; Brater DC
    J Pharmacol Exp Ther; 1989 Sep; 250(3):772-8. PubMed ID: 2778714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration.
    Sjöström PA; Kron BG; Odlind BG
    Eur J Clin Pharmacol; 1993; 45(2):135-9. PubMed ID: 8223834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit.
    Pichette V; Geadah D; du Souich P
    Drug Metab Dispos; 1999 Jan; 27(1):81-5. PubMed ID: 9884313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
    Takamura N; Maruyama T; Chosa E; Kawai K; Tsutsumi Y; Uryu Y; Yamasaki K; Deguchi T; Otagiri M
    Drug Metab Dispos; 2005 Apr; 33(4):596-602. PubMed ID: 15640375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic study of intravenous furosemide in nephrotic syndrome in children].
    Lenoir G; Halter D; Seligman R; Dreuz C
    Arch Fr Pediatr; 1978 Feb; 35(2):187-97. PubMed ID: 637676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.
    Jespersen B
    Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of binding in distribution of furosemide: where is nonrenal clearance?
    Branch RA
    Fed Proc; 1983 Apr; 42(6):1699-702. PubMed ID: 6832389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal secretion of [35-S]furosemide and depression by albumin binding.
    Bowman RH
    Am J Physiol; 1975 Jul; 229(1):93-8. PubMed ID: 1147061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome.
    González-Martín G; Bravo I; Ibarra N; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):598-601. PubMed ID: 6668097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.
    Rane A; Villeneuve JP; Stone WJ; Nies AS; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1978 Aug; 24(2):199-207. PubMed ID: 679597
    [No Abstract]   [Full Text] [Related]  

  • 13. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding inhibitors restore furosemide potency in tubule fluid containing albumin.
    Kirchner KA; Voelker JR; Brater DC
    Kidney Int; 1991 Sep; 40(3):418-24. PubMed ID: 1724020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of protein binding on the elimination of acetazolamide by the isolated perfused rat kidney: evidence of albumin-mediated tubular secretion.
    Taft DR; Sweeney KR
    J Pharmacol Exp Ther; 1995 Aug; 274(2):752-60. PubMed ID: 7636739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impaired plasma protein binding of furosemide in nephrotic syndrome and uremia].
    Takahashi F
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):665-80. PubMed ID: 7176178
    [No Abstract]   [Full Text] [Related]  

  • 17. Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition.
    Nishio T; Takamura N; Nishii R; Tokunaga J; Yoshimoto M; Kawai K
    Nephrol Dial Transplant; 2008 Jul; 23(7):2304-10. PubMed ID: 18390890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).
    Ponto LL; Schoenwald RD
    Clin Pharmacokinet; 1990 May; 18(5):381-408. PubMed ID: 2185908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic synthesis and albumin distribution in the primary nephrotic syndrome (PNS). as demonstrated by immunofluoresce.
    Exaire E; González F; Stoopen M; Aguirre J; Pérez A; Gutierrez ML
    Arch Invest Med (Mex); 1978; 9(3):485-502. PubMed ID: 708187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.